Radiation oncology firm Accuray said that a large study using its CyberKnife robotic radiosurgery system validated use of the technology for prostate cancer treatment.
In a study that followed 304 patients for a median of five years, 97% of patients with low-risk and 90.7% of those with intermediate-risk prostate cancer remained cancer-free throughout that time period, according to Accuray.
CyberKnife treatment was also shown to produce low levels of toxicity similar to the levels produced by other radiation treatment options. In addition, 75% of patients who were sexually potent prior to CyberKnife had preserved sexual function afterward, Accuray said.
Results of the study, which was led by Dr. Alan Katz of Flushing Radiation Oncology, were published in the May issue of Radiation Oncology.
